[go: up one dir, main page]

WO2002000275A1 - Materiaux polymeriques biocompatibles - Google Patents

Materiaux polymeriques biocompatibles Download PDF

Info

Publication number
WO2002000275A1
WO2002000275A1 PCT/GB2001/002786 GB0102786W WO0200275A1 WO 2002000275 A1 WO2002000275 A1 WO 2002000275A1 GB 0102786 W GB0102786 W GB 0102786W WO 0200275 A1 WO0200275 A1 WO 0200275A1
Authority
WO
WIPO (PCT)
Prior art keywords
polymer
moieties
iii
support material
porous layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2001/002786
Other languages
English (en)
Inventor
John Neil Devine
David John Kemmish
Brian Wilson
Ian Griffiths
Kenneth Malcolm Seargeant
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Victrex Manufacturing Ltd
Original Assignee
Victrex Manufacturing Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Victrex Manufacturing Ltd filed Critical Victrex Manufacturing Ltd
Priority to AU74322/01A priority Critical patent/AU7432201A/en
Publication of WO2002000275A1 publication Critical patent/WO2002000275A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/56—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials

Definitions

  • This invention relates to bio-compatible polymeric materials and particularly, although not exclusively, relates to a method of making a medical device, for example a prosthesis or part thereof using such a material and such a device per. se.
  • bio-compatible materials do not exist passively when introduced into human or animal bodies but become integrated, for example osseo-integrated therewith.
  • materials which have optimum physical (e.g. strength, modulus, wear resistance) and chemical (e.g. chemical stability, bio-stability, bio- compatibility) properties which are readily integratable with human or animal body tissues.
  • a method of making a medical device or part thereof including the step of forming a porous layer on the outside of a support material, wherein said porous layer includes a polymer having a moiety of formula
  • phenyl moieties in units I, II, and III are independently optionally substituted and optionally cross- linked; and wherein m,r,s,t,v,w and z independently represent zero or a positive integer, E and E' independently represent an oxygen or a sulphur atom or a direct link, G represents an oxygen or sulphur atom, a direct link or a -O-Ph-0- moiety where Ph represents a phenyl group and Ar is selected from one of the following moieties (i)*, (i)**, (i) to (x) which is bonded via one or more of its phenyl moieties to adjacent moieties
  • the invention extends to a method of making a medical device or part thereof, the method including the step of forming a porous layer on the outside of the support material from a polymer having moieties I, II and/or III as described.
  • any alkyl, akenyl or alkynyl moiety suitably has up to 8, preferably up to 6, more preferably up to 4, especially up to 2, carbon atoms and may be of straight chain or, where possible, of branched chain structure.
  • methyl and ethyl are preferred alkyl groups and C 2 alkenyl and alkynyl groups are preferred.
  • optional substituents of an alkyl group may include halogen atoms, for example fluorine, chlorine, bromine and iodine atoms, and nitro, cyano, alkoxy, hydroxy, amino, alkylamino, sulphinyl, alkylsulphinyl, sulphonyl, alkylsulphonyl, amido, alkylamido, alkoxycarbonyl , haloalkoxycarbonyl and haloalkyl groups.
  • optionally substituted alkyl groups are unsubstituted.
  • Said porous layer preferably includes pores
  • surface pores which open at the surface of said porous layer thereby to enable tissues to grow into the pores to aid integration of said medical device and/or part when introduced into a human or animal body.
  • surface pores have a diameter of at least lO ⁇ m, preferably at least 25 ⁇ m, more preferably at least 50 ⁇ , especially at least lOO ⁇ m, although it should be appreciated that a surface may include pores having diameters which are larger or smaller than those mentioned.
  • the average diameter of said surface pores is at least lO ⁇ m, preferably at least 25 ⁇ m, more preferably at least 50 ⁇ m, especially at least lOO ⁇ m.
  • the average diameter may be greater than 200 ⁇ m or even greater than 300 ⁇ m.
  • the average diameter may be less than 600 ⁇ m, suitably less than 500 ⁇ m, preferably less than 400 ⁇ m, more preferably less than 300 ⁇ m, especially less than 200 ⁇ m.
  • the diameter may be measured using a low magnification optical microscope with scale in visual frame.
  • Said porous layer preferably includes a majority of pores of at least lO ⁇ m, preferably at least 25 ⁇ m, more preferably at least 50 ⁇ m, especially at least lOO ⁇ m.
  • a “majority” may mean at least 50%, suitably greater than 65%, preferably greater than 80%, more preferably greater then 95%, especially greater than 98%.
  • Said porous layer may have a density of at least 400 mg.cm "3 , preferably at least 500 mg.cm "3 , more preferably at least 600 mg.cm "3 . Said density may be 1000 mg.cm "3 or less.
  • Said porous layer may have an average porosity of at least 20%, suitably at least 30%, preferably at least 40%, more preferably at least 50%.
  • the porosity may be less than 90%, suitably less than 80%, preferably less than 70%. In some cases, the porosity may be less than 60%. Porosity may be measured by any suitable technique, for example by mercury intrusion porosimetry.
  • Said porous layer preferably includes pore interconnections having average diameters of at least 50 ⁇ m, for example as measured using mercury intrusion porosimetry.
  • Said porous layer preferably includes a three- dimensional network of interconnected pores. Three- dimensional networks as described rarely connect through straight channels. Preferably, said porous layer includes a network of interconnected pores throughout its volume with substantially no straight paths therein longer than the diameter of the largest pore .
  • Said porous layer preferably has a thickness of at least lOO ⁇ m, more preferably at least 250 ⁇ m, especially at least 500 ⁇ m.
  • the thickness may be 10mm or less, preferably 5mm or less .
  • a phenyl moiety may have 1,4- or 1,3-, especially 1,4-, linkages to moieties to which it is bonded.
  • Said polymer may include more than one different type of repeat unit of formula I; more than one different type of repeat unit of formula II; and more than one different type of repeat unit of formula III. Preferably, however, only one type of repeat unit of formula I, II and/or III is provided.
  • Said moieties I, II and III are suitably repeat units.
  • units I, II and/or III are suitably bonded to one another - that is, with no other atoms or groups being bonded between units I, II, and III.
  • phenyl moieties in units I, II or III are optionally substituted, they may be optionally substituted by one or more halogen, especially fluorine and chlorine, atoms or alkyl, cycloalkyl or phenyl groups.
  • Preferred alkyl groups are C ⁇ _ 10 , especially C ⁇ _ 4 , alkyl groups.
  • Preferred cycloalkyl groups include cyclohexyl and multicyclic groups, for example adamantyl.
  • R q is selected from the group consisting of alkyls, perfluoralkyls and aryls
  • Sulphonate moieties may also be preferred in some circumstances .
  • said phenyl moieties are not optionally- substituted prior to formation of said porous layer. If, however, they are substituted, they are preferably substituted by moieties that can withstand injection moulding of the polymer. Phenyl moieties may be optionally-substituted (especially sulphonated) after formation of said layer as hereinafter described.
  • said polymer is cross-linked, it is suitably cross-linked so as to improve its properties.
  • Any suitable means may be used to effect cross-linking.
  • cross-linking between polymer chains may be effected via sulphur atoms on respective chains.
  • said polymer is not optionally cross-linked as described.
  • the respective phenylene moieties may independently have 1,4- or 1,3-linkages to the other moieties in the repeat units of formulae II and/or III.
  • said phenylene moieties have 1,4- linkages.
  • the polymeric chain of the polymer does not include a -S- moiety.
  • G represents a direct link.
  • a represents the mole % of units of formula I in said polymer, suitably wherein each unit I is the same;
  • "b” represents the mole % ⁇ of units of formula II in said polymer, suitably wherein each unit II is the same;
  • "c” represents the mole % of units of formula III in said polymer, suitably wherein each unit III is the same.
  • " a is “ in the range 45-100, " more preferably in the range 45-55, especially in the range 48-52.
  • the sum of b and c is in the range 0-55, more preferably in the range 45-55, especially in the range 48- 52.
  • the ratio of a to the sum of b and c is in the range 0.9 to 1.1 and, more preferably, is about 1.
  • the sum of a, b and c is at least 90, preferably at least 95, more preferably at least 99, especially about 100.
  • said polymer consists essentially of moieties I, II and/or III.
  • Said polymer may be a homopolymer having a repeat unit of general formula
  • A, B, C and D independently represent 0 or 1 and E,E',G,Ar,m,r,s,t,v,w and z are as described in any statement herein.
  • said polymer may be a homopolymer having a repeat unit of general formula
  • A, B, C, and D independently represent 0 or 1 and E, E', G, Ar, m, r, s, t, v, w and z are as described in any statement herein.
  • m is in the range 0-3, more preferably 0-2, especially 0-1.
  • r is in the range 0-3, more preferably 0-2, especially 0-1.
  • t is in the range 0-3, more preferably 0-2, especially 0-1.
  • s is 0 or 1.
  • v is 0 or 1.
  • w is 0 or 1.
  • z is 0 or 1.
  • said polymer is a homopolymer having a repeat unit of general formula IV.
  • Ar is selected from the following moieties
  • the middle phenyl may be 1,4- or 1,3- substituted.
  • (xv) is selected from a 1,2-, 1,3-, or a 1,5- moiety
  • (xvi) is selected from a 1,6-, 2,3-, 2,6- or a 2,7- moiety
  • (xvii) is selected from a 1,2-, 1,4-, 1,5- , 1,8- or a 2,6- moiety.
  • One preferred class of polymers does not include any moieties of formula III, but suitably only includes moieties of formulae I and/or II.
  • said polymer is a homopolymer or random or block copolymer as described, said homopolymer or copolymer suitably includes a repeat unit of general formula IV.
  • Such a polymer may, in some embodiments, not include any repeat unit of general formula V.
  • Suitable moieties Ar are moieties (i)*, (i) , (ii) ,
  • polymers which consist essentially of phenyl moieties in conjunction with ketone and/or ether moieties. That is, in the preferred class, the polymer does not include repeat units which include -S-, -S0 2 - or aromatic groups other than phenyl .
  • Preferred polymers of the type described include :
  • B represents 0 (i.e. polyetherketone) ;
  • E' represent oxygen atoms
  • G represents a direct link
  • m represents 0, w represents 1, r represents 0, s represents 1 and
  • a and B represent 1. (i.e. polyetherketoneetherketoneketone) .
  • polymers described in (a) and (b) are preferred, with the polymer described in (a) being especially preferred.
  • the glass transition temperature (T g ) of said polymer may be at least 135°C, suitably at least 150°C, preferably at least 154°C, more preferably at least 160°C, especially at least 164°C. In some cases, the Tg may be at least 170°C, or at least 190°C or greater than 250°C or even
  • Said polymer may have an inherent viscosity (IV) of at least 0.1, suitably at least 0.3, preferably at least 0.4, more preferably at least 0.6, especially at least 0.7
  • RV reduced viscosity
  • both RV and IV both suitably employ a viscometer having a solvent flow time of approximately 2 minutes .
  • the main peak of the melting endotherm (Tm) for said polymer (if crystalline) may be at least 300°C.
  • said polymer has at least some crystallinity or is crystallisable.
  • the existence and/or extent of crystallinity in a polymer is preferably measured by wide angle X-ray diffraction, for example as described by Blundell and Osborn (Polymer 24, 953, 1983) .
  • crystallinity may be assessed by Differential Scanning Calorimetry (DSC) .
  • Said polymer may have a number average molecular weight in the range 2000-80000. Preferably said molecular weight is at least 14,000. The molecular weight may be less than 60,000.
  • Said porous layer may include one or more fillers for providing desired properties.
  • Said porous layer preferably incorporates an X-ray contrast medium. Fillers and/or said
  • X-ray contrast medium is/are preferably distributed substantially uniformly throughout said porous layer.
  • an X-ray contrast medium suitably comprises less than 25wt%, preferably "less-"than 20wt%, more preferably less than 15wt%, especially less than 10wt% of said porous layer. Where it is provided, at least 2wt% may be included.
  • Preferred X-ray contrast mediums are particulate and preferably are inorganic. They preferably have low solubility in body fluids. They preferably also have a sufficient density compared to that of the polymeric material to create an image if a compounded mixture of the polymer and contrast medium are X-ray imaged. Barium sulphate and zirconium oxide are examples of X-ray contrast media. Said particulate material is suitably physically held in position by entrapment within the porous layer.
  • the pore size and density of a said porous layer can be a function of the X-ray contrast medium and/or other fillers present.
  • the resultant pores are predominantly in the range 30 to 60 ⁇ m, whereas at 10% filler level, the pores are predominantly in the range 70 to 120 ⁇ m.
  • Said support material may be made out of any suitable material for example a metal or plastics material.
  • said support material comprises a polymer which preferably includes a moiety of formula I and/or a moiety of formula II and/or a moiety of formula
  • Said polymer of the support material may have any feature of the polymer in said porous layer except, preferably, said support material has lower porosity compared to the porous layer and preferably is substantially non-porous.
  • Said support material and said porous layer may include the same material or a different material , but preferably both materials include phenyl moieties, carbonyl and/or sulphone moieties, and ether or
  • said support material preferably includes moieties I, II and/or III and the preferred polymers which include moieties I, II and III described above with reference to the porous layer are preferred for said support material, phenyl groups of said moieties are preferably not optionally-substituted or cross-linked.
  • said support material comprises any of the polymers described in paragraphs (a) to (e) above and, of these, the polymers in (a) and (b) are preferred with the polymer in (a) being especially preferred.
  • Said support material preferably comprises a major amount of said polymer.
  • said support material comprises more than one polymer having moieties I, II and/or III the sum of the amounts of respective said polymers preferably represents a major amount.
  • a “major” amount may mean greater than 50wt%, suitably greater than 65wt%, preferably greater than 80wt%, more preferably greater than 95wt%, especially greater than 98wt% of the referenced material is present relative to the total weight of relevant material present.
  • Said support material preferably comprises a unitary arrangement. That is, it preferably does not comprise a series of layers of material or include areas thereof having a higher concentration of one component compared to another.
  • Said support material preferably has a thickness in at least one region thereof of at least 5mm, preferably at least 10mm, more preferably at least 20mm.
  • Said support material preferably does not consist of a coating
  • Said support material suitably has a tensile strength
  • the tensile strength may be less than 360, suitably less than 250, preferably less than 140 MPa. It preferably has an elongate at break (according to ISO R527) of at least 40, preferably at least 50%. It preferably has a tensile modulus (according to ISO R527) of greater than 2.5, preferably greater than 3, especially greater than 3.5 GPa. The tensile modulus may be less than 40, suitably less than 30, preferably less than 20, more preferably less than 10 GPa.
  • flexural strength (according to ASTM D695) of at least 100, more preferably at least 110, especially at least 115 MPa.
  • the flexural strength may be less than 650, preferably less than 400, more preferably less than 260, especially less than 200 MPa.
  • the flexural modulus may be less than 60, suitably less than 25, preferably less than
  • a continuous carbon fibre polyetheretherketone may typically have a tensile strength of about 350 MPa, a tensile modulus of 36 GPa, an elongation of 2%, a flexural modulus of 50 GPa and a flexural strength of 620 MPa.
  • a said porous layer may be provided on any part of said medical device or part thereof which may come into contact with body fluids in use.
  • the method of the first aspect may include a first method type which includes treating a region on the outside of said support material to render it porous.
  • the region which is treated may be a part of said support material (in which case it suitably includes a polymer having moieties I, II and/or III described herein) or may comprise a layer of a polymer having moieties I, II and/or III which is applied to the support material (which preferably comprises a polymer having moieties I, II and/or III) prior to the treatment.
  • said layer which is to be rendered porous is preferably part of or associated with said support material prior to said layer being rendered porous.
  • said layer which is to be rendered porous comprises a polymer having moieties I, II and/or III, wherein phenyl moieties in moieties I, II and/or III are not optionally-substituted or optionally cross-linked.
  • Said layer which is to be rendered porous optionally includes an X-ray contrast medium as described therein.
  • said support material is arranged in a shape which represents or is a precursor of a medical device or part thereof.
  • a said layer of polymer may be applied to said support material.
  • said support material having at least a layer of a said polymer having moieties I, II and/or III is placed in an environment which is at a temperature of at least 20 °C above the glass transition temperature of the polymer and at least 30°C below the melting temperature of the polymer.
  • the environment is suitably pressurised, suitably at 20-50 MPa, with a supercritical fluid, especially carbon dioxide. Consequently, the fluid diffuses into the polymer.
  • the fluid pressure may be released and preferably the temperature in the environment is reduced, suitably relatively rapidly, below the glass transition temperature of the polymer.
  • the layer on the outside of the support material is thereafter found to be porous .
  • the properties and/or arrangement of the porous layer formed can be varied to suit any particular application and/or desired characteristics .
  • the polymer rendered porous may not be functionalised in the method and, accordingly, the polymer prior to and subsequent to the treatment is chemically unchanged.
  • a useful porous layer may be formed using supercritical carbon dioxide at 260 °C and 34.5 MPa (5- 7 00 ⁇ — s-ig-)- for——5—ous. - - ⁇
  • a surface of said support material having at least a layer of said polymer having moieties I, II and/or III is contacted with a solvent in order to dissolve polymer at said surface.
  • said support material may be immersed in the solvent.
  • the polymer is caused to precipitate at the surface by diluting the solvent, for example by contacting said surface with a solvent which is not capable of solvating the polymer.
  • the depth of the porous layer and/or pore sizes are dependent upon the nature of the solvent, the solvent concentration, the temperature and the time of contact of said solvent with said support material .
  • suitable solvents that may be used to dissolve include sulphuric acid, methanesulphonic acid and phenol/dichlorobenzene .
  • solvents may, in addition to solvating the polymer, chemically react with it to functionalise it.
  • Sulphonating solvents for example sulphuric acid such as 98% sulphuric acid, may sulphonate polymers of the type described.
  • said solvent may sulphonate phenyl moieties in -0-(Ph) n -0- moieties in said polymer where Ph represents a phenyl moiety and n represents an integer (preferably 1) .
  • a porous functionalised (e.g. sulphonated) layer may be produced in the method.
  • the polymer rendered porous may be chemically changed during the treatment, for example by functionalisation of phenyl moieties as described.
  • The- metho -o the- -f-ir-st—-aspect— ay- include a second method type wherein a layer of material which is arranged to be porous (hereinafter "precursor material") is applied to the support material, wherein said precursor material includes a polymer having moieties I, II and/or III as described herein.
  • Said precursor material suitably includes at least 30wt%, preferably at least 40wt%, more preferably at least 50wt%, especially at least 60wt% of a said polymer having moieties I, II and/or III.
  • Said precursor material may include an X-ray contrast medium as described. Any desired depth of said precursor material may be applied to the support according to the desired depth of the porous layer.
  • said precursor material is applied as a porous material .
  • a foamed material may be applied to the support material.
  • Supercritical carbon dioxide may be used as described with reference to said first embodiment of said first method.
  • said polymer having moieties I, II and/or III and any other components which are to make up the precursor material may be heated in an environment at a temperature of at least 20 °C above the glass transition temperature of the polymer used and at least 30 °C below the melting temperature of the polymer.
  • the environment is suitably pressurised with a supercritical fluid, especially carbon dioxide so that the fluid diffuses into the polymer.
  • the molten mixture may be extruded into an atmosphere of lower pressure, whereupon as the pressure on the melt reduces upon exiting an extrusion orifice, a foam is formed.
  • This foam may be injection moulded on to the support material or, alternatively, the molten mixture and the support material may be co-extruded so that the foam is di-recfc-1y---t-ransferred--t-o —the—support --material as it exits an extruder.
  • said polymer of said precursor material is not chemically changed, for example functionalised in the method and, accordingly, said polymer before and after contact with said support material is chemically unchanged.
  • said precursor material is arranged to be rendered porous, suitably after it has been contacted with the support material.
  • said precursor material comprises a material (hereinafter a "removable material") which can be removed, for example dissolved out of said precursor material, when said precursor material is present on the support material, whereby a porous structure is produced by virtue of the voids defined in regions from which said removable material has been removed.
  • the method preferably includes contacting the precursor ' material, when it is present on said support material, with solvent which solubilises the removable material but not the polymer having moieties I, II and/or III.
  • the polymer is semi-crystalline so as to render it less soluble in solvents that may be used to solubilise the removable material.
  • said polymer of said precursor material is not functionalised in the method, so said polymer before and after contact with said solvent is preferably chemically unchanged.
  • said removable material may comprise an amorphous high temperature polymer or polymers which is/are preferably blended with said polymer having moieties I, II and/or III, wherein each amorphous polymer used is incompatible with said polymer having moieties I, II and/or III.
  • Blending is preferably by a melt process, suitably using a twin screw extruder. The total amount of said amorphous polymer in the blend may be less than 40%wt.
  • An X-ray contrast medium may be included in the blend as described herein.
  • the blend may be contacted with the support material for example by being injection moulded or extruded directly onto the support material.
  • the morphology is that of a continuous matrix of the larger volume component (e.g, the polymer having moieties I, II and/or III) with domains of the lower volume component
  • the method may then involve immersing the composite comprising support material and precursor material in a solvent which will dissolve out the removable material leaving a microporous structure of the polymer having moieties I, II and/or III that is firmly attached to the support.
  • the solvent may be selected to effect dissolution according to the identity of the removable material .
  • the identity and/or physical form of the amorphous polymer affects the nature of the porous layer produced in the method. Whilst polysulphone or polyethersulphones may be used, there is a tendency for the resultant pores produced to -be- -too- -small- for bone -ingrowth. It is preferred that polymers are selected which, when removed, yield pores, preferably a majority thereof, in the range 50-500 ⁇ m. Suitable polymers may be less compatible with said polymer having moieties I, II and/or III (especially the preferred examples thereof described herein) than polyethersulphone or polysulphone is with said polymer. Said removable material is preferably a polymer which does not include ether groups in its polymer chain.
  • said removable material has a polymer backbone of the same type as described for said polymer having moieties I, II and/or III, there are preferably bulky groups pendent from the backbone to render it incompatible with said polymer having moieties I, II and/or III. It is especially preferred for said removable material not to be a polyketone or polysulphone polymer. Examples of preferred polymers are high temperature nylons, high temperature silane polymers and polymers that incorporate fluorine atoms .
  • said removable material may comprise a fugitive compound which is preferably blended with said polymer having moieties I, II and/or III.
  • Said fugitive compound is preferably thermally stable at 400 °C and preferably includes particles, preferably a majority t ereof, in the range 50-500 ⁇ m. At least 5wt%, preferably at least 20wt%, more preferably at least 15wt% of said fugitive compound may be present in the precursor material .
  • the amount of said compound in said precursor material is preferably less than 60wt%, more preferably less than 50wt%, especially 40wt% or less.
  • Said precursor material may include an X-ray contrast medium, as described, for -example in- the- range- -3- ⁇ 2-5wt% ⁇
  • Preferred fugitive compounds are inorganic, especially inorganic salts.
  • the polymer having moieties I, II and/or III is filled with said fugitive compound and said X-ray contrast medium, if provided, using a melt processing technique.
  • the blend may be contacted with the support material for example by being injection moulded or extruded directly onto the support material. After solidification, the composite of support material and precursor material is immersed in a solvent to remove the fugitive compound and yield a microporous three- dimensional surface.
  • the solvent used is preferably an acid, for example hydrochloric acid.
  • the acid used has a negligible effect on the polymer having moieties I, II and/or III itself.
  • a porous material may be prepared as described in applicant's co-pending application no GB 0101098.2.
  • the method described therein may be used to prepare a porous (foamed) layer on the outside of a support material .
  • the layer may be formed by heating a mixture which includes a said polymer having moieties I, II and/or III and a decomposable material comprising a magnesium moiety and a hydroxide moiety (e.g. magnesium hydroxide) to a foaming temperature at or above the decomposition temperature of the decomposable material .
  • the porous layer may be extruded onto the support material .
  • -the method may include a further treatment of a porous layer after it has been formed, for example to reveal elements of the microporous structure that would otherwise not be exposed to body fluids, in use. Further treatment may involve machining the porous layer after it has been prepared. Furthermore, in some embodiments, the method may involve removing the porous layer in its entirety, for example in regions of the medical device or part thereof that do not contact body fluids in use or otherwise are not required to be adapted for bone ingrowth in osseo-integration.
  • the method of the first aspect may include associating bio-compatible moieties with said polymer which includes moieties I, II and/or III of said porous layer.
  • the method preferably includes the step of treating said polymer with a material for providing bio-compatible moieties (hereinafter "BCM material").
  • BCM material may be arranged to provide any of the bio-compatible moieties described hereinafter.
  • Said polymer may be provided as a solid.
  • said bio-compatible moieties are caused to become associated with a surface of said porous layer of said solid.
  • Said solid is preferably shaped so as to represent at least a part of a device for use in medical applications, as described above.
  • bio-compatible material formed is not engineered or otherwise treated in a manner which may result in substantial depletion of the bio-compatible moieties associated with its surface.
  • bio-compatible has generally been used to refer to a material which is compatible with use in medical applications, for example by not being toxic or otherwise harmful to living materials . It also encompasses materials which have a biological or physiological effect when associated with living materials.
  • said bio-compatible polymeric material has improved or enhanced bio-compatibility compared to said polymer having moieties I, II and/or III in said porous layer, in the absence of associated bio-compatible moieties .
  • Bio-compatible moieties suitably include moieties arranged to reduce adverse biological reactions when the bio-compatible polymeric material is introduced into (or otherwise associated with) a human or animal body.
  • adverse biological reactions associated with introduction into a human or animal body of said polymer having said bio-compatible moieties may be less compared to use of the same polymer but which does not include associated bio-compatible moieties.
  • Bio-compatible moieties referred to herein suitably refer to moieties which are compatible with use in medical applications, for example by not being toxic or otherwise harmful to living material. Such bio-compatible moieties may be arranged to bond (for example to form ionic or covalent bonds) or otherwise interact with materials present in human or animal ⁇ bodies "in “ “order ⁇ t ⁇ “Improve their integration and acceptance by such bodies.
  • a said bio-compatible moiety may be selected from an ⁇ anticoagulant agent such as heparin and heparin sulfate, an antithrombotic agent, a clotting agent, a platelet agent, an anti-inflammatory agent, an antibody, an antigen, an immunoglobulin, a defence agent, an enzyme, a hormone, a growth factor, a neurotransmitter, a cytokine, a blood agent, a regulatory agent, a transport agent, a fibrous agent, a protein such as avidin, a glycoprotein, a globular protein, a structural protein, a membrane protein and a cell attachment protein, a peptide such as a glycopeptide, a structural peptide, a membrane peptide and a cell attachment peptide, a proteoglycan, a toxin, ' an antibiotic agent, an antibacterial agent, an antimicrobial agent such as pencillin, ticarcillin, carbenicillin, ampicillin, oxacillian, ce
  • poly (ethylene glycol) (PEG) poly (ethylene oxide) (PEO) , ethylene oxide- propylene oxide block co-polymers, poly (N-vinyl-2- pyrrolidone) (P VP) , poly (2-hydroxyethyl methacrylate)
  • HEMA HEMA co-polymers
  • PVA poly (vinyl alcohol)
  • PVA polyacrylamide
  • PMMA polyacrylamide
  • PMMA suitably having a PEG chain on each of the side groups, polysiloxanes (e.g. polydimethylsiloxanes (PDMS) ) , ionic water-soluble polymers like poly (acrylic acid) (PAAc) ) and a polyurethane .
  • PDMS polydimethylsiloxanes
  • PAAc polyacrylic acid
  • said bio-compatible moieties may comprise bone morphogenic protein (BMP) as described in US4563489 and patents cited therein and the contents of the aforesaid are incorporated herein.
  • BMP bone morphogenic protein
  • Said BMP may be provided in combination, for example in admixture, with a physiologically acceptable biodegradable organic polymer and said biodegradable polymer may be associated with said at least two moieties of said polymer of said bio- compatible polymeric material, for example by being covalently bonded to said at least two moieties.
  • the combination of said biodegradable polymer and BMP defines said bio-compatible moieties.
  • Said biodegradable polymer is preferably a biodegradable polylactic acid; or alternatively, other physiologically acceptable biodegradable organic polymers which are structurally equivalent to polylactic acid can be used as the delivery system for BMP.
  • examples include poly(hydroxy organic carboxylic acids) e.g. poly(hydroxy aliphatic carboxylic acids) , polyglycollic acid, polyglactin, polyglactic acid and poly adonic acids.
  • said bio-compatible moieties may be selected from inorganic crystalline structures, inorganic -amorphous - structures, organic crystalline structures and organic amorphous structures .
  • Preferred bio-compatible moieties are phosphorous based ceramics, for example calcium-phosphorous ceramics .
  • Phosphates in general are suitable but calcium phosphates and calcium apatite are preferred.
  • bio-compatible moieties may be associated by any suitable means with the porous layer, for example by covalent bond(s) , hydrogen bond(s) , encapsulation in a matrix which is bonded to or otherwise interacts with said layer or by ionic interaction (s) , it is preferred that there are covalent bonds between the bio-compatible moieties and said polymer having moieties I, II and/or III in said porous layer or there are ionic interactions between said bio-compatible moieties and said polymer.
  • the method may include functionalising said porous layer after its formation thereby to enable association with said bio-compatible moieties.
  • said polymer which includes moieties I, II and/or III may be functionalised prior to or during formation of said porous layer.
  • An example of the latter is Example 2 hereinafter wherein the polymer is sulphonated during formation of said porous layer.
  • the porous layer may be treated with a diisocyanate and a diol thereby to associate a polyurethane with said porous layer.
  • the porous layer may be treated with a diisocyanate and a diol thereby to associate a polyurethane with said porous layer .
  • said support material is preferably formed into a shape which represents or is a precursor of a medical device or part thereof . Formation into a shape may use any suitable method, for example, moulding, machining of a blank, extrusion or the like. Then, said porous layer is formed on the outside of the support material in desired regions thereof using a method described herein. The porous layer may be further treated for example to functionalise it and/or to associate bio-compatible moieties with it.
  • the method may be used for making any type of medical device or part thereof (as described in the introduction of this specification)
  • the medical device or part thereof is preferably for an orthopaedic implant, especially for a body joint, for example a hip or knee joint or spine fusion device.
  • the invention extends to a method of making a medical device or part thereof, the method comprising: forming a material into a shape which represents or is a precursor of a device for use in medical applications wherein said material comprises a polymer; and treating material in said shape in order to define a porous layer on the outside of said shape, wherein said porous layer comprises a polymer having moieties I, II and/or III as described herein.
  • a medical device or part thereof which includes a support material and a porous layer on the
  • porous layer includes a polymer having a moiety of formula I and/or of formula II and/or of formula III as described according to the first aspect wherein said polymer is optionally associated with bio-compatible moieties.
  • said support material also comprises a polymer having a moiety of formula I and/or II and/or III.
  • said polymer in the support material and said polymer in said porous layer have the same polymeric backbone. They may differ in terms of whether phenyl moieties are functionalised and/or since bio-compatible moieties may be associated with said porous layer.
  • the polymer is polyetheretherketone or polyetherketone or a functionalised derivative thereof
  • a polymer having a moiety of formula I and/or II and/or III may be prepared as described in PCT/GB99/02833.
  • the invention extends to a method of making a medical device or part thereof, the method including the step of forming a layer (hereinafter an "X-ray contrast layer”) on the outside of a support material, wherein said layer includes an X-ray contrast medium.
  • a layer hereinafter an "X-ray contrast layer”
  • Said X-ray contrast layer may have any feature of the porous layer described herein.
  • Said support material may have any feature of a said support material described in any statement herein.
  • said support material includes a lower amount of X-ray contrast medium than said X-ray contrast layer.
  • said support material includes substantially no X-ray contrast medium.
  • PEEK Trade Mark
  • PEK Trade Mark
  • Hydrofy GS 1.5 (Trade Mark) a mineral containing >90% magnesium hydroxide obtained from Nuova Sima Sri of Genga,
  • the plaque had a porous surface of sulphonated PEEKTM with predominantly 50 - 400 ⁇ m pores.
  • Example 3 Formation of a porous surface on polyaryleth ⁇ retherketone using calcium carbonate.
  • Polyaryletheretherketone 450G (Victrex pic) was mixed with nominally 250 ⁇ m particulate calcium carbonate at 40% by weight using a 25 mm single screw extruder. The resultant mixture was injection moulded into 3.2 mm thick plaques (150 x 150 mm) . The plaques were transferred to a bath of 2M Hydrochloric acid. After a soak time of 2 hours the resultant plaque had a three dimensional microporous surface. The pores were measured in the range 60 to 300 ⁇ m.
  • the size of the resulting particles in the polymer were reduced from nominally 250 ⁇ m to a range that yielded predominantly 60-300 ⁇ m pores.
  • 450G polyaryletheretherketone supplied by Victrex pic was mixed with nominally 100 micron barium sulphate powder (Merck, UK) in a Marion Tumble blender for 30 minutes. The resultant mixture was fed into a 32 mm single screw extruder. The mixture was extruded and cooled as a lace in air, prior to granulation. The mixed pellets were placed in trays (approximately 2.5 cm deep) in an air circulating oven at 130 °C for 5 hours. The pellets were then injection molded using a Neggri Bossi 100 tones clamping force moulder to form 150 mm x 150 mm x 6 mm plaques .
  • Plaques were then placed in a cavity 5 mm larger than the plaque depth and 10 mm wider than the plaque width and length.
  • the cavity was placed in 200 tpsi heated platen press, fitted with thermocouples and a water cooling system.
  • the nominal temperature of the platens was set to 280 C and the clamping force was increased to a maximum value.
  • the temperature was allowed to stabilize prior to the cavity being pressurised with supercritical carbon dioxide at 40 MPa. The pressure and temperature was maintained for 5 hours .
  • the sample was removed from the tool when the thermocouple readings fell below 80 C.
  • the plaque had the surface finish machined off (approximately 0.25 mm) to reveal a complex microstructure of pores .
  • the pores were predominately in the size range 50 to 500 microns and discrete.
  • High viscosity polyaryletheretherketone (450G) has been used in a series of experiments to produce foamed components of densities varying in the range 0.35 to 0.90 g cm "3 .
  • the supercritical fluid used was C0 2 and was introduced to the melt after compaction via a poppet valve. After the introduction of the supercritical fluid the temperatures used to process the melt were reduced from 400 to 300 °C.
  • the extrudate was expelled through an adjustable slit die as a foam on to a strip of PEEK film cut to fit onto a laboratory sized band caster. As the bandcaster rotated the extruded material formed a drawn foamed layer on the surface of the PEEK film.
  • A- sect-ion- of- this- foamed composite strip was removed, mounted on a solid plaque and the foamed surface subjected to mechanical abrassion so as to revove the surface layer.
  • the exposed surface structure was seen under an optical microscope as comprising a complex microstructure of pores. The pores were predominantly in the size range 50 to 200 microns.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Manufacture Of Porous Articles, And Recovery And Treatment Of Waste Products (AREA)

Abstract

L'invention concerne un procédé de fabrication d'un appareil médical ou d'une partie de ce dernier, consistant à former une couche poreuse disposée à l'extérieur d'un matériau de support, dans lequel la couche poreuse est, selon des modes de réalisation favoris, sélectionnée à partir de polyéthercétone et de polyétheréthercétone. On peut préparer la couche poreuse selon un procédé qui comprend le traitement d'une zone située à l'extérieur d'un matériau de support en vue de le rendre poreux. De plus, ce traitement peut nécessiter la diffusion d'un fluide supercritique à l'intérieur du polymère ou l'utilisation d'un solvant pour dissoudre le polymère présent à la surface, puis d'une précipitation subséquente en surface. Autrement, un matériau disposé de manière à être poreux peut être appliqué sur le matériau de support dans lequel ce matériau poreux peut être une mousse. Selon un autre mode de réalisation, un matériau peut être rendu poreux après avoir été mis en contact avec le matériau de support par exemple, grâce au fait que celui-ci comprend un matériau amovible comme un sel, par exemple. L'invention concerne également des appareils médicaux et des procédés de fabrication de ces appareils.
PCT/GB2001/002786 2000-06-24 2001-06-22 Materiaux polymeriques biocompatibles Ceased WO2002000275A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU74322/01A AU7432201A (en) 2000-06-24 2001-06-22 Bio-compatible polymeric materials

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0015430A GB0015430D0 (en) 2000-06-24 2000-06-24 Bio-compatible polymeric materials
GB0015430.2 2000-06-24

Publications (1)

Publication Number Publication Date
WO2002000275A1 true WO2002000275A1 (fr) 2002-01-03

Family

ID=9894274

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/002786 Ceased WO2002000275A1 (fr) 2000-06-24 2001-06-22 Materiaux polymeriques biocompatibles

Country Status (3)

Country Link
AU (1) AU7432201A (fr)
GB (1) GB0015430D0 (fr)
WO (1) WO2002000275A1 (fr)

Cited By (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003077965A1 (fr) * 2002-03-13 2003-09-25 University Of Nottingham Composition de polymere chargee de cellules
WO2004006973A1 (fr) * 2002-07-06 2004-01-22 Kensey Nash Corporation Structure resorbable pour traiter et soigner des tissus defectueux
EP1454946A1 (fr) * 2003-02-24 2004-09-08 Basf Aktiengesellschaft Mousse à cellules ouvertes de polymère à haut point de fusion,
EP1468703A1 (fr) 2003-04-15 2004-10-20 Depuy Products, Inc. Dispositif orthopédique implantable
US7087084B2 (en) 1999-10-22 2006-08-08 Archus Orthopedics, Inc. Method for replacing a natural facet joint with a prosthesis having an artificial facet joint structure
US7290347B2 (en) 2004-04-22 2007-11-06 Archus Orthopedics, Inc. Facet joint prosthesis measurement and implant tools
US7406775B2 (en) 2004-04-22 2008-08-05 Archus Orthopedics, Inc. Implantable orthopedic device component selection instrument and methods
US7549984B2 (en) 2004-06-16 2009-06-23 Pneumrx, Inc. Method of compressing a portion of a lung
US7608104B2 (en) 2003-05-14 2009-10-27 Archus Orthopedics, Inc. Prostheses, tools and methods for replacement of natural facet joints with artifical facet joint surfaces
US7670282B2 (en) 2004-06-14 2010-03-02 Pneumrx, Inc. Lung access device
US7674293B2 (en) 2004-04-22 2010-03-09 Facet Solutions, Inc. Crossbar spinal prosthesis having a modular design and related implantation methods
WO2010030993A1 (fr) 2008-09-12 2010-03-18 Pneumrx, Inc. Modèles améliorés et/ou rallongés de dispositifs de réduction de volume pulmonaire à effraction minimale et leur mise en place
US7691145B2 (en) 1999-10-22 2010-04-06 Facet Solutions, Inc. Prostheses, systems and methods for replacement of natural facet joints with artificial facet joint surfaces
US7766938B2 (en) 2004-07-08 2010-08-03 Pneumrx, Inc. Pleural effusion treatment device, method and material
US7766891B2 (en) 2004-07-08 2010-08-03 Pneumrx, Inc. Lung device with sealing features
WO2010135352A1 (fr) 2009-05-18 2010-11-25 Pneumrx, Inc. Modification de section transversale durant le déploiement d'un dispositif allongé de réduction du volume pulmonaire
US7846162B2 (en) 2005-05-18 2010-12-07 Sonoma Orthopedic Products, Inc. Minimally invasive actuable bone fixation devices
EP2292188A2 (fr) 2002-11-27 2011-03-09 Conformis, Inc. Outils chirurgicaux pouvant etre selectionnes en fonction du patient
US7909825B2 (en) 2006-11-22 2011-03-22 Sonoma Orthepedic Products, Inc. Fracture fixation device, tools and methods
US7914556B2 (en) 2005-03-02 2011-03-29 Gmedelaware 2 Llc Arthroplasty revision system and method
EP2324799A2 (fr) 2004-11-24 2011-05-25 Conformis, Inc. Dispositifs d'arthroplastie de l'articulation du genou, sélectionnables selon le patient
EP2335654A1 (fr) 2003-11-25 2011-06-22 Conformis, Inc. Dispositifs d'arthroplastie d'articulation du genou selectionnables selon le patient
USRE43282E1 (en) 1998-09-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Assessing the condition of a joint and devising treatment
US8157837B2 (en) 2006-03-13 2012-04-17 Pneumrx, Inc. Minimally invasive lung volume reduction device and method
US8187303B2 (en) 2004-04-22 2012-05-29 Gmedelaware 2 Llc Anti-rotation fixation element for spinal prostheses
US8221461B2 (en) 2004-10-25 2012-07-17 Gmedelaware 2 Llc Crossbar spinal prosthesis having a modular design and systems for treating spinal pathologies
US8231655B2 (en) 2003-07-08 2012-07-31 Gmedelaware 2 Llc Prostheses and methods for replacement of natural facet joints with artificial facet joint surfaces
US8287541B2 (en) 2005-05-18 2012-10-16 Sonoma Orthopedic Products, Inc. Fracture fixation device, tools and methods
EP2520255A1 (fr) 2005-11-21 2012-11-07 Vertegen, Inc. Dispositifs et procédés de traitement de facettes articulaires lombaires, d'articulations uncovertébrales, d'articulations costovertébrales et d'autres articulations
US8398681B2 (en) 2004-08-18 2013-03-19 Gmedelaware 2 Llc Adjacent level facet arthroplasty devices, spine stabilization systems, and methods
US8409254B2 (en) 2003-05-14 2013-04-02 Gmedelaware 2 Llc Prostheses, tools and methods for replacement of natural facet joints with artificial facet joint surfaces
US8496686B2 (en) 2005-03-22 2013-07-30 Gmedelaware 2 Llc Minimally invasive spine restoration systems, devices, methods and kits
WO2013131066A1 (fr) 2012-03-02 2013-09-06 Conformis, Inc. Implants du genou stabilisés postérieurs adaptés au patient, conceptions et procédés et outils associés
EP2649951A2 (fr) 2006-02-06 2013-10-16 ConforMIS, Inc. Dispositifs d'arthroplastie articulaire et outils chirurgicaux selectionnables par le patient
US8702755B2 (en) 2006-08-11 2014-04-22 Gmedelaware 2 Llc Angled washer polyaxial connection for dynamic spine prosthesis
EP2754419A2 (fr) 2011-02-15 2014-07-16 Conformis, Inc. Implants orthopédiques améliorés et adaptés au patient, conceptions et outils associés
WO2014151557A2 (fr) 2013-03-15 2014-09-25 Pneumrx, Inc. Structures d'implant compressif à réduction de volume pulmonaire dans les voies aériennes à soulagement de couple
US8862202B2 (en) 1998-09-14 2014-10-14 The Board Of Trustees Of The Leland Stanford Junior University Assessing the condition of a joint and preventing damage
US8888800B2 (en) 2006-03-13 2014-11-18 Pneumrx, Inc. Lung volume reduction devices, methods, and systems
US8951260B2 (en) 2001-05-25 2015-02-10 Conformis, Inc. Surgical cutting guide
US8961516B2 (en) 2005-05-18 2015-02-24 Sonoma Orthopedic Products, Inc. Straight intramedullary fracture fixation devices and methods
US9017334B2 (en) 2009-02-24 2015-04-28 Microport Orthopedics Holdings Inc. Patient specific surgical guide locator and mount
US9023050B2 (en) 2001-05-25 2015-05-05 Conformis, Inc. Surgical tools for arthroplasty
US9056016B2 (en) 2003-12-15 2015-06-16 Gmedelaware 2 Llc Polyaxial adjustment of facet joint prostheses
US9055953B2 (en) 2001-05-25 2015-06-16 Conformis, Inc. Methods and compositions for articular repair
US9060820B2 (en) 2005-05-18 2015-06-23 Sonoma Orthopedic Products, Inc. Segmented intramedullary fracture fixation devices and methods
US9066728B2 (en) 2001-05-25 2015-06-30 Conformis, Inc. Surgical tools facilitating increased accuracy, speed and simplicity in performing joint arthroplasty
US9125639B2 (en) 2004-11-23 2015-09-08 Pneumrx, Inc. Steerable device for accessing a target site and methods
US9155574B2 (en) 2006-05-17 2015-10-13 Sonoma Orthopedic Products, Inc. Bone fixation device, tools and methods
US9286686B2 (en) 1998-09-14 2016-03-15 The Board Of Trustees Of The Leland Stanford Junior University Assessing the condition of a joint and assessing cartilage loss
WO2016046715A1 (fr) * 2014-09-25 2016-03-31 Università Degli Studi Di Trento Procédé de fabrication de supports poreux pour des utilisations biomédicales et supports correspondants
US9308053B2 (en) 2006-02-06 2016-04-12 Conformis, Inc. Patient-specific joint arthroplasty devices for ligament repair
US9326780B2 (en) 2006-02-06 2016-05-03 Conformis, Inc. Patient selectable joint arthroplasty devices and surgical tools incorporating anatomical relief
US9402633B2 (en) 2006-03-13 2016-08-02 Pneumrx, Inc. Torque alleviating intra-airway lung volume reduction compressive implant structures
WO2016134409A1 (fr) * 2015-02-27 2016-09-01 The University Of Sydney Matériaux biomédicaux implantables
US9486226B2 (en) 2012-04-18 2016-11-08 Conformis, Inc. Tibial guides, tools, and techniques for resecting the tibial plateau
US9486558B2 (en) 2003-03-27 2016-11-08 Locate Therapeutics Limited Porous matrix
US9579110B2 (en) 2001-05-25 2017-02-28 Conformis, Inc. Patient selectable joint arthroplasty devices and surgical tools
US9642632B2 (en) 2009-02-24 2017-05-09 Microport Orthopedics Holdings Inc. Orthopedic surgical guide
US9649117B2 (en) 2009-02-24 2017-05-16 Microport Orthopedics Holdings, Inc. Orthopedic surgical guide
US9675471B2 (en) 2012-06-11 2017-06-13 Conformis, Inc. Devices, techniques and methods for assessing joint spacing, balancing soft tissues and obtaining desired kinematics for joint implant components
EP3187153A2 (fr) 2005-09-30 2017-07-05 Conformis, Inc. Implant porteur
US9770278B2 (en) 2014-01-17 2017-09-26 Arthrex, Inc. Dual tip guide wire
US9801637B2 (en) 2006-03-13 2017-10-31 Pneumrx, Inc. Genetically-associated chronic obstructive pulmonary disease treatment
US9814499B2 (en) 2014-09-30 2017-11-14 Arthrex, Inc. Intramedullary fracture fixation devices and methods
US9931438B2 (en) * 2008-01-28 2018-04-03 Ngk Spark Plug Co., Ltd. Article with foamed surface, implant and method of producing the same
US10390838B1 (en) 2014-08-20 2019-08-27 Pneumrx, Inc. Tuned strength chronic obstructive pulmonary disease treatment
US10537334B2 (en) 2013-10-25 2020-01-21 Pneumrx, Inc. Genetically-associated chronic obstructive pulmonary disease treatment
CN111184913A (zh) * 2020-01-13 2020-05-22 吉林大学 一种基于聚醚醚酮的人工骨复合材料及其制备方法
CN111939319A (zh) * 2019-05-17 2020-11-17 北京化工大学 一种生物活性多孔聚醚醚酮及其制备方法与应用
CN112972764A (zh) * 2021-03-19 2021-06-18 吉林大学 一种具有多尺度孔的聚醚醚酮骨修复材料及其制备方法
CN113398328A (zh) * 2021-05-12 2021-09-17 上海云合景从新材料科技有限公司 一种多孔聚醚醚酮及其制备方法与应用
EP3746139B1 (fr) 2018-02-02 2023-07-05 Evonik Operations GmbH Implant de genou polymère à gradient fonctionnel pour des propriétés de fixation, résistance à l'usure, et mécaniques améliorée et sa fabrication
US12108959B2 (en) 2019-05-29 2024-10-08 Wright Medical Technology, Inc. Preparing a tibia for receiving tibial implant component of a replacement ankle
CN119015496A (zh) * 2024-08-14 2024-11-26 苏州真懿医疗有限公司 聚醚醚酮听小骨假体的制备方法及聚醚醚酮听小骨假体
US12383287B2 (en) 2009-02-24 2025-08-12 Microport Orthopedics Holdings, Inc. Systems and methods for installing an orthopedic implant
US12396739B2 (en) 2020-01-17 2025-08-26 Wright Medical Technology, Inc. Guidance tools, systems, and methods
US12440227B2 (en) 2021-02-24 2025-10-14 Wright Medical Technology, Inc. Preparing a tibia for receiving tibial implant component of a replacement ankle

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0269256A1 (fr) * 1986-11-04 1988-06-01 Pfizer Hospital Products Group, Inc. Méthode pour former sur les implants chirurgicaux une surface d'ancrage du tissu vivant
EP0283187A2 (fr) * 1987-03-17 1988-09-21 Imperial Chemical Industries Plc Pellicules et bandes
US4859715A (en) * 1984-05-18 1989-08-22 Raychem Corporation Microporous poly (arylether ketone) article
WO1991009079A1 (fr) * 1989-12-14 1991-06-27 Farmitalia Carlo Erba S.R.L. Utilisation de fluides surcritiques pour obtenir des eponges poreuses de polymeres biodegradables
EP0610953A1 (fr) * 1993-02-11 1994-08-17 Minnesota Mining And Manufacturing Company Articles thermoplastiques expansés et leur méthode de préparation
EP0659389A1 (fr) * 1993-10-20 1995-06-28 Schneider (Europe) Ag Endoprothèse
US5969020A (en) * 1993-08-13 1999-10-19 Poly-Med, Inc. Microporous polymeric foams and microtextured surfaces
EP1099468A2 (fr) * 1999-11-10 2001-05-16 DEUTSCHE INSTITUTE FÜR TEXTIL- UND FASERFORSCHUNG STUTTGART Stiftung des öffentlichen Rechts Membrane microporeuse hydrophile

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859715A (en) * 1984-05-18 1989-08-22 Raychem Corporation Microporous poly (arylether ketone) article
EP0269256A1 (fr) * 1986-11-04 1988-06-01 Pfizer Hospital Products Group, Inc. Méthode pour former sur les implants chirurgicaux une surface d'ancrage du tissu vivant
EP0283187A2 (fr) * 1987-03-17 1988-09-21 Imperial Chemical Industries Plc Pellicules et bandes
WO1991009079A1 (fr) * 1989-12-14 1991-06-27 Farmitalia Carlo Erba S.R.L. Utilisation de fluides surcritiques pour obtenir des eponges poreuses de polymeres biodegradables
EP0610953A1 (fr) * 1993-02-11 1994-08-17 Minnesota Mining And Manufacturing Company Articles thermoplastiques expansés et leur méthode de préparation
US5969020A (en) * 1993-08-13 1999-10-19 Poly-Med, Inc. Microporous polymeric foams and microtextured surfaces
EP0659389A1 (fr) * 1993-10-20 1995-06-28 Schneider (Europe) Ag Endoprothèse
EP1099468A2 (fr) * 1999-11-10 2001-05-16 DEUTSCHE INSTITUTE FÜR TEXTIL- UND FASERFORSCHUNG STUTTGART Stiftung des öffentlichen Rechts Membrane microporeuse hydrophile

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RENARDY M ET AL: "MEMBRANES FOR A BIOHYBRID PANCREAS", ADVANCES IN BIOMATERIALS, 1990, pages 633 - 638, XP001034375, ISSN: 0272-3840 *

Cited By (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE43282E1 (en) 1998-09-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Assessing the condition of a joint and devising treatment
US8862202B2 (en) 1998-09-14 2014-10-14 The Board Of Trustees Of The Leland Stanford Junior University Assessing the condition of a joint and preventing damage
US9286686B2 (en) 1998-09-14 2016-03-15 The Board Of Trustees Of The Leland Stanford Junior University Assessing the condition of a joint and assessing cartilage loss
US8066740B2 (en) 1999-10-22 2011-11-29 Gmedelaware 2 Llc Facet joint prostheses
US7691145B2 (en) 1999-10-22 2010-04-06 Facet Solutions, Inc. Prostheses, systems and methods for replacement of natural facet joints with artificial facet joint surfaces
US8092532B2 (en) 1999-10-22 2012-01-10 Gmedelaware 2 Llc Facet arthroplasty devices and methods
US7087084B2 (en) 1999-10-22 2006-08-08 Archus Orthopedics, Inc. Method for replacing a natural facet joint with a prosthesis having an artificial facet joint structure
US8070811B2 (en) 1999-10-22 2011-12-06 Gmedelaware 2 Llc Facet arthroplasty devices and methods
US7608106B2 (en) 1999-10-22 2009-10-27 Archus Orthopedics, Inc. Facet arthroplasty devices and methods
US9579110B2 (en) 2001-05-25 2017-02-28 Conformis, Inc. Patient selectable joint arthroplasty devices and surgical tools
US9072531B2 (en) 2001-05-25 2015-07-07 Conformis, Inc. Patient selectable joint arthroplasty devices and surgical tools
US8951259B2 (en) 2001-05-25 2015-02-10 Conformis, Inc. Patient selectable joint arthroplasty devices and surgical tools
US9023050B2 (en) 2001-05-25 2015-05-05 Conformis, Inc. Surgical tools for arthroplasty
US9216025B2 (en) 2001-05-25 2015-12-22 Conformis, Inc. Joint arthroplasty devices and surgical tools
US9055953B2 (en) 2001-05-25 2015-06-16 Conformis, Inc. Methods and compositions for articular repair
US9107680B2 (en) 2001-05-25 2015-08-18 Conformis, Inc. Patient selectable joint arthroplasty devices and surgical tools
US8951260B2 (en) 2001-05-25 2015-02-10 Conformis, Inc. Surgical cutting guide
US9125673B2 (en) 2001-05-25 2015-09-08 Conformis, Inc. Joint arthroplasty devices and surgical tools
US8998915B2 (en) 2001-05-25 2015-04-07 Conformis, Inc. Joint arthroplasty devices and surgical tools
US9295482B2 (en) 2001-05-25 2016-03-29 Conformis, Inc. Patient selectable joint arthroplasty devices and surgical tools
US9125672B2 (en) 2001-05-25 2015-09-08 Conformis, Inc. Joint arthroplasty devices and surgical tools
US9084617B2 (en) 2001-05-25 2015-07-21 Conformis, Inc. Patient selectable joint arthroplasty devices and surgical tools
US9107679B2 (en) 2001-05-25 2015-08-18 Conformis, Inc. Patient selectable joint arthroplasty devices and surgical tools
US9186161B2 (en) 2001-05-25 2015-11-17 Conformis, Inc. Surgical tools for arthroplasty
US9066728B2 (en) 2001-05-25 2015-06-30 Conformis, Inc. Surgical tools facilitating increased accuracy, speed and simplicity in performing joint arthroplasty
US9358018B2 (en) 2001-05-25 2016-06-07 Conformis, Inc. Joint arthroplasty devices and surgical tools
WO2003077965A1 (fr) * 2002-03-13 2003-09-25 University Of Nottingham Composition de polymere chargee de cellules
US7049348B2 (en) 2002-07-06 2006-05-23 Kensey Nash Corporation Resorbable structure for treating and healing of tissue defects
WO2004006973A1 (fr) * 2002-07-06 2004-01-22 Kensey Nash Corporation Structure resorbable pour traiter et soigner des tissus defectueux
EP2292189A2 (fr) 2002-11-27 2011-03-09 Conformis, Inc. Outils chirurgicaux pouvant etre selectionnes en fonction du patient
EP2292188A2 (fr) 2002-11-27 2011-03-09 Conformis, Inc. Outils chirurgicaux pouvant etre selectionnes en fonction du patient
EP1454946A1 (fr) * 2003-02-24 2004-09-08 Basf Aktiengesellschaft Mousse à cellules ouvertes de polymère à haut point de fusion,
US7655705B2 (en) 2003-02-24 2010-02-02 Basf Aktiengesellschaft Open-cell foam composed of high-melting point plastics
US10232087B2 (en) 2003-03-27 2019-03-19 Locate Therapeutics Limited Porous matrix
US9486558B2 (en) 2003-03-27 2016-11-08 Locate Therapeutics Limited Porous matrix
AU2004201549B2 (en) * 2003-04-15 2009-08-13 Depuy Products, Inc. Implantable orthopaedic device and method for making the same
US7938861B2 (en) 2003-04-15 2011-05-10 Depuy Products, Inc. Implantable orthopaedic device and method for making the same
EP2191852A3 (fr) * 2003-04-15 2010-07-21 DePuy Products, Inc. Dispositif orthopédique implantable
EP2191852A2 (fr) 2003-04-15 2010-06-02 DePuy Products, Inc. Dispositif orthopédique implantable
JP2004313794A (ja) * 2003-04-15 2004-11-11 Depuy Products Inc 移植可能な整形外科的器具および整形外科的器具の製造方法
EP1468703A1 (fr) 2003-04-15 2004-10-20 Depuy Products, Inc. Dispositif orthopédique implantable
US8409254B2 (en) 2003-05-14 2013-04-02 Gmedelaware 2 Llc Prostheses, tools and methods for replacement of natural facet joints with artificial facet joint surfaces
US7608104B2 (en) 2003-05-14 2009-10-27 Archus Orthopedics, Inc. Prostheses, tools and methods for replacement of natural facet joints with artifical facet joint surfaces
US9198766B2 (en) 2003-05-14 2015-12-01 Gmedelaware 2 Llc Prostheses, tools, and methods for replacement of natural facet joints with artificial facet joint surfaces
US8523907B2 (en) 2003-07-08 2013-09-03 Gmedelaware 2 Llc Prostheses, tools and methods for replacement of natural facet joints with artificial facet joint surfaces
US8231655B2 (en) 2003-07-08 2012-07-31 Gmedelaware 2 Llc Prostheses and methods for replacement of natural facet joints with artificial facet joint surfaces
EP2335654A1 (fr) 2003-11-25 2011-06-22 Conformis, Inc. Dispositifs d'arthroplastie d'articulation du genou selectionnables selon le patient
US9056016B2 (en) 2003-12-15 2015-06-16 Gmedelaware 2 Llc Polyaxial adjustment of facet joint prostheses
US8675930B2 (en) 2004-04-22 2014-03-18 Gmedelaware 2 Llc Implantable orthopedic device component selection instrument and methods
US8425557B2 (en) 2004-04-22 2013-04-23 Gmedelaware 2 Llc Crossbar spinal prosthesis having a modular design and related implantation methods
US7290347B2 (en) 2004-04-22 2007-11-06 Archus Orthopedics, Inc. Facet joint prosthesis measurement and implant tools
US8491635B2 (en) 2004-04-22 2013-07-23 Gmedelaware 2 Llc Crossbar spinal prosthesis having a modular design and related implantation methods
US7406775B2 (en) 2004-04-22 2008-08-05 Archus Orthopedics, Inc. Implantable orthopedic device component selection instrument and methods
US8187303B2 (en) 2004-04-22 2012-05-29 Gmedelaware 2 Llc Anti-rotation fixation element for spinal prostheses
US7674293B2 (en) 2004-04-22 2010-03-09 Facet Solutions, Inc. Crossbar spinal prosthesis having a modular design and related implantation methods
US8496687B2 (en) 2004-04-22 2013-07-30 Gmedelaware 2 Llc Crossbar spinal prosthesis having a modular design and related implantation methods
US7670282B2 (en) 2004-06-14 2010-03-02 Pneumrx, Inc. Lung access device
US7775968B2 (en) 2004-06-14 2010-08-17 Pneumrx, Inc. Guided access to lung tissues
US7549984B2 (en) 2004-06-16 2009-06-23 Pneumrx, Inc. Method of compressing a portion of a lung
US7766938B2 (en) 2004-07-08 2010-08-03 Pneumrx, Inc. Pleural effusion treatment device, method and material
US7766891B2 (en) 2004-07-08 2010-08-03 Pneumrx, Inc. Lung device with sealing features
US8398681B2 (en) 2004-08-18 2013-03-19 Gmedelaware 2 Llc Adjacent level facet arthroplasty devices, spine stabilization systems, and methods
US8221461B2 (en) 2004-10-25 2012-07-17 Gmedelaware 2 Llc Crossbar spinal prosthesis having a modular design and systems for treating spinal pathologies
US9125639B2 (en) 2004-11-23 2015-09-08 Pneumrx, Inc. Steerable device for accessing a target site and methods
US10034999B2 (en) 2004-11-23 2018-07-31 Pneumrx, Inc. Steerable device for accessing a target site and methods
EP2324799A2 (fr) 2004-11-24 2011-05-25 Conformis, Inc. Dispositifs d'arthroplastie de l'articulation du genou, sélectionnables selon le patient
US7914556B2 (en) 2005-03-02 2011-03-29 Gmedelaware 2 Llc Arthroplasty revision system and method
US8496686B2 (en) 2005-03-22 2013-07-30 Gmedelaware 2 Llc Minimally invasive spine restoration systems, devices, methods and kits
US9060820B2 (en) 2005-05-18 2015-06-23 Sonoma Orthopedic Products, Inc. Segmented intramedullary fracture fixation devices and methods
US7914533B2 (en) 2005-05-18 2011-03-29 Sonoma Orthopedic Products, Inc. Minimally invasive actuable bone fixation devices
US8961516B2 (en) 2005-05-18 2015-02-24 Sonoma Orthopedic Products, Inc. Straight intramedullary fracture fixation devices and methods
US7846162B2 (en) 2005-05-18 2010-12-07 Sonoma Orthopedic Products, Inc. Minimally invasive actuable bone fixation devices
US8287541B2 (en) 2005-05-18 2012-10-16 Sonoma Orthopedic Products, Inc. Fracture fixation device, tools and methods
US8287539B2 (en) 2005-05-18 2012-10-16 Sonoma Orthopedic Products, Inc. Fracture fixation device, tools and methods
US7942875B2 (en) 2005-05-18 2011-05-17 Sonoma Orthopedic Products, Inc. Methods of using minimally invasive actuable bone fixation devices
EP3187153A2 (fr) 2005-09-30 2017-07-05 Conformis, Inc. Implant porteur
EP2520255A1 (fr) 2005-11-21 2012-11-07 Vertegen, Inc. Dispositifs et procédés de traitement de facettes articulaires lombaires, d'articulations uncovertébrales, d'articulations costovertébrales et d'autres articulations
US9308053B2 (en) 2006-02-06 2016-04-12 Conformis, Inc. Patient-specific joint arthroplasty devices for ligament repair
US9220517B2 (en) 2006-02-06 2015-12-29 Conformis, Inc. Patient selectable joint arthroplasty devices and surgical tools
US9326780B2 (en) 2006-02-06 2016-05-03 Conformis, Inc. Patient selectable joint arthroplasty devices and surgical tools incorporating anatomical relief
EP2649951A2 (fr) 2006-02-06 2013-10-16 ConforMIS, Inc. Dispositifs d'arthroplastie articulaire et outils chirurgicaux selectionnables par le patient
EP2671521A2 (fr) 2006-02-06 2013-12-11 ConforMIS, Inc. Dispositifs d'arthroplastie articulaire et outils chirurgicaux selectionnables par le patient
US9220516B2 (en) 2006-02-06 2015-12-29 Conformis, Inc. Patient selectable joint arthroplasty devices and surgical tools
EP2671522A2 (fr) 2006-02-06 2013-12-11 ConforMIS, Inc. Dispositifs d'arthroplastie articulaire et outils chirurgicaux selectionnables par le patient
EP2671520A2 (fr) 2006-02-06 2013-12-11 ConforMIS, Inc. Dispositifs d'arthroplastie articulaire et outils chirurgicaux selectionnables par le patient
EP2710967A2 (fr) 2006-02-06 2014-03-26 ConforMIS, Inc. Dispositifs d'arthroplastie articulaire et outils chirurgicaux selectionnables par le patient
EP3167821A1 (fr) 2006-03-13 2017-05-17 PneumRx, Inc. Dispositifs de réduction du volume pulmonaire
US9402632B2 (en) 2006-03-13 2016-08-02 Pneumrx, Inc. Lung volume reduction devices, methods, and systems
US8888800B2 (en) 2006-03-13 2014-11-18 Pneumrx, Inc. Lung volume reduction devices, methods, and systems
US8157837B2 (en) 2006-03-13 2012-04-17 Pneumrx, Inc. Minimally invasive lung volume reduction device and method
EP3143962A1 (fr) 2006-03-13 2017-03-22 Pneumrx, Inc. Dispositifs, procédés et systèmes de réduction du volume pulmonaire invasif minimal
US9782558B2 (en) 2006-03-13 2017-10-10 Pneumrx, Inc. Minimally invasive lung volume reduction devices, methods, and systems
US9474533B2 (en) 2006-03-13 2016-10-25 Pneumrx, Inc. Cross-sectional modification during deployment of an elongate lung volume reduction device
DE202007019683U1 (de) 2006-03-13 2015-09-16 PNEUMRX. lnc. Minimalinvasive Lungenvolumenreduktionsvorrichtungen und -systeme
US8932310B2 (en) 2006-03-13 2015-01-13 Pneumrx, Inc. Minimally invasive lung volume reduction devices, methods, and systems
US9402971B2 (en) 2006-03-13 2016-08-02 Pneumrx, Inc. Minimally invasive lung volume reduction devices, methods, and systems
US10226257B2 (en) 2006-03-13 2019-03-12 Pneumrx, Inc. Lung volume reduction devices, methods, and systems
EP2842501A1 (fr) 2006-03-13 2015-03-04 Pneumrx, Inc. Dispositifs, procédés et systèmes de réduction du volume pulmonaire invasif minimal
US9801637B2 (en) 2006-03-13 2017-10-31 Pneumrx, Inc. Genetically-associated chronic obstructive pulmonary disease treatment
US9402633B2 (en) 2006-03-13 2016-08-02 Pneumrx, Inc. Torque alleviating intra-airway lung volume reduction compressive implant structures
US10188397B2 (en) 2006-03-13 2019-01-29 Pneumrx, Inc. Torque alleviating intra-airway lung volume reduction compressive implant structures
US9155574B2 (en) 2006-05-17 2015-10-13 Sonoma Orthopedic Products, Inc. Bone fixation device, tools and methods
US8702755B2 (en) 2006-08-11 2014-04-22 Gmedelaware 2 Llc Angled washer polyaxial connection for dynamic spine prosthesis
US7909825B2 (en) 2006-11-22 2011-03-22 Sonoma Orthepedic Products, Inc. Fracture fixation device, tools and methods
US9259250B2 (en) 2006-11-22 2016-02-16 Sonoma Orthopedic Products, Inc. Fracture fixation device, tools and methods
US9931438B2 (en) * 2008-01-28 2018-04-03 Ngk Spark Plug Co., Ltd. Article with foamed surface, implant and method of producing the same
US10660990B2 (en) 2008-01-28 2020-05-26 Ngk Spark Plug Co., Ltd. Article with foamed surface, implant and method of producing the same
EP2848208A2 (fr) 2008-09-12 2015-03-18 Pneumrx, Inc. Dispositifs mini-invasifs de réduction du volume pulmonaire et leur administration
EP3305234A1 (fr) 2008-09-12 2018-04-11 PneumRx, Inc. Dispositifs de réduction du volume pulmonaire minimalement invasifs et methodes de planification de telles procédures
US10285707B2 (en) 2008-09-12 2019-05-14 Pneumrx, Inc. Enhanced efficacy lung volume reduction devices, methods, and systems
WO2010030993A1 (fr) 2008-09-12 2010-03-18 Pneumrx, Inc. Modèles améliorés et/ou rallongés de dispositifs de réduction de volume pulmonaire à effraction minimale et leur mise en place
US9192403B2 (en) 2008-09-12 2015-11-24 Pneumrx, Inc. Elongated lung volume reduction devices, methods, and systems
US9173669B2 (en) 2008-09-12 2015-11-03 Pneumrx, Inc. Enhanced efficacy lung volume reduction devices, methods, and systems
US10058331B2 (en) 2008-09-12 2018-08-28 Pneumrx, Inc. Enhanced efficacy lung volume reduction devices, methods, and systems
US9642632B2 (en) 2009-02-24 2017-05-09 Microport Orthopedics Holdings Inc. Orthopedic surgical guide
US11464527B2 (en) 2009-02-24 2022-10-11 Microport Orthopedics Holdings Inc. Systems and methods for installing an orthopedic implant
US9675365B2 (en) 2009-02-24 2017-06-13 Microport Orthopedics Holdings Inc. System and method for anterior approach for installing tibial stem
US9649117B2 (en) 2009-02-24 2017-05-16 Microport Orthopedics Holdings, Inc. Orthopedic surgical guide
US12383287B2 (en) 2009-02-24 2025-08-12 Microport Orthopedics Holdings, Inc. Systems and methods for installing an orthopedic implant
US12256944B2 (en) 2009-02-24 2025-03-25 MicroPort Orthopedic Holdings, Inc. Patient specific surgical guide locator and mount
US9566075B2 (en) 2009-02-24 2017-02-14 Microport Orthopedics Holdings Inc. Patient specific surgical guide locator and mount
US12220134B2 (en) 2009-02-24 2025-02-11 Microport Orthopedics Holdings Inc. System for forming a patient specific surgical guide mount
US9883870B2 (en) 2009-02-24 2018-02-06 Microport Orthopedics Holdings Inc. Method for forming a patient specific surgical guide mount
US9901353B2 (en) 2009-02-24 2018-02-27 Microport Holdings Inc. Patient specific surgical guide locator and mount
US11911046B2 (en) 2009-02-24 2024-02-27 Microport Orthopedics Holdings, Inc. Patient specific surgical guide locator and mount
US11779347B2 (en) 2009-02-24 2023-10-10 Microport Orthopedics Holdings Inc. System for forming a patient specific surgical guide mount
US9949747B2 (en) 2009-02-24 2018-04-24 Microport Orthopedics Holdings, Inc. Systems and methods for installing an orthopedic implant
US11779356B2 (en) 2009-02-24 2023-10-10 Microport Orthopedics Holdings, Inc. Orthopedic surgical guide
US10039557B2 (en) 2009-02-24 2018-08-07 Micorport Orthopedics Holdings, Inc. Orthopedic surgical guide
US11534186B2 (en) 2009-02-24 2022-12-27 Microport Orthopedics Holdings Inc. Orthopedic surgical guide
US9113914B2 (en) 2009-02-24 2015-08-25 Microport Orthopedics Holdings Inc. Method for forming a patient specific surgical guide mount
US9089342B2 (en) 2009-02-24 2015-07-28 Microport Orthopedics Holdings Inc. Patient specific surgical guide locator and mount
US11389177B2 (en) 2009-02-24 2022-07-19 Microport Orthopedics Holdings Inc. Method for forming a patient specific surgical guide mount
US9017334B2 (en) 2009-02-24 2015-04-28 Microport Orthopedics Holdings Inc. Patient specific surgical guide locator and mount
US11154305B2 (en) 2009-02-24 2021-10-26 Microport Orthopedics Holdings Inc. Patient specific surgical guide locator and mount
US10973536B2 (en) 2009-02-24 2021-04-13 Microport Orthopedics Holdings, Inc. Orthopedic surgical guide
US10512476B2 (en) 2009-02-24 2019-12-24 Microport Orthopedics Holdings, Inc. Orthopedic surgical guide
US10660654B2 (en) 2009-02-24 2020-05-26 Microport Orthopedics Holdings Inc. Method for forming a patient specific surgical guide mount
US10646238B2 (en) 2009-02-24 2020-05-12 Microport Orthopedics Holdings, Inc. Systems and methods for installing an orthopedic implant
WO2010135352A1 (fr) 2009-05-18 2010-11-25 Pneumrx, Inc. Modification de section transversale durant le déploiement d'un dispositif allongé de réduction du volume pulmonaire
EP2754419A2 (fr) 2011-02-15 2014-07-16 Conformis, Inc. Implants orthopédiques améliorés et adaptés au patient, conceptions et outils associés
WO2013131066A1 (fr) 2012-03-02 2013-09-06 Conformis, Inc. Implants du genou stabilisés postérieurs adaptés au patient, conceptions et procédés et outils associés
US9486226B2 (en) 2012-04-18 2016-11-08 Conformis, Inc. Tibial guides, tools, and techniques for resecting the tibial plateau
US9675471B2 (en) 2012-06-11 2017-06-13 Conformis, Inc. Devices, techniques and methods for assessing joint spacing, balancing soft tissues and obtaining desired kinematics for joint implant components
WO2014151557A2 (fr) 2013-03-15 2014-09-25 Pneumrx, Inc. Structures d'implant compressif à réduction de volume pulmonaire dans les voies aériennes à soulagement de couple
EP3632375A1 (fr) 2013-03-15 2020-04-08 PneumRx Inc. Atténuation du couple dans des structures d'implant de compression de réduction du volume pulmonaire à l'intérieur des voies respiratoires
EP3357455A2 (fr) 2013-03-15 2018-08-08 PneumRx, Inc. Atténuation du couple dans des structures d'implant de compression de réduction du volume pulmonaire à l'intérieur des voies respiratoires
US10537334B2 (en) 2013-10-25 2020-01-21 Pneumrx, Inc. Genetically-associated chronic obstructive pulmonary disease treatment
US9770278B2 (en) 2014-01-17 2017-09-26 Arthrex, Inc. Dual tip guide wire
US10390838B1 (en) 2014-08-20 2019-08-27 Pneumrx, Inc. Tuned strength chronic obstructive pulmonary disease treatment
WO2016046715A1 (fr) * 2014-09-25 2016-03-31 Università Degli Studi Di Trento Procédé de fabrication de supports poreux pour des utilisations biomédicales et supports correspondants
US10548648B2 (en) 2014-09-30 2020-02-04 Arthrex, Inc. Intramedullary fracture fixation devices and methods
US9814499B2 (en) 2014-09-30 2017-11-14 Arthrex, Inc. Intramedullary fracture fixation devices and methods
WO2016134409A1 (fr) * 2015-02-27 2016-09-01 The University Of Sydney Matériaux biomédicaux implantables
EP3746139B1 (fr) 2018-02-02 2023-07-05 Evonik Operations GmbH Implant de genou polymère à gradient fonctionnel pour des propriétés de fixation, résistance à l'usure, et mécaniques améliorée et sa fabrication
CN111939319A (zh) * 2019-05-17 2020-11-17 北京化工大学 一种生物活性多孔聚醚醚酮及其制备方法与应用
US12108959B2 (en) 2019-05-29 2024-10-08 Wright Medical Technology, Inc. Preparing a tibia for receiving tibial implant component of a replacement ankle
CN111184913B (zh) * 2020-01-13 2021-06-04 吉林大学 一种基于聚醚醚酮的人工骨复合材料及其制备方法
CN111184913A (zh) * 2020-01-13 2020-05-22 吉林大学 一种基于聚醚醚酮的人工骨复合材料及其制备方法
US12396739B2 (en) 2020-01-17 2025-08-26 Wright Medical Technology, Inc. Guidance tools, systems, and methods
US12440227B2 (en) 2021-02-24 2025-10-14 Wright Medical Technology, Inc. Preparing a tibia for receiving tibial implant component of a replacement ankle
CN112972764A (zh) * 2021-03-19 2021-06-18 吉林大学 一种具有多尺度孔的聚醚醚酮骨修复材料及其制备方法
CN113398328A (zh) * 2021-05-12 2021-09-17 上海云合景从新材料科技有限公司 一种多孔聚醚醚酮及其制备方法与应用
CN113398328B (zh) * 2021-05-12 2022-08-12 上海云合景从新材料科技有限公司 一种多孔聚醚醚酮及其制备方法与应用
CN119015496A (zh) * 2024-08-14 2024-11-26 苏州真懿医疗有限公司 聚醚醚酮听小骨假体的制备方法及聚醚醚酮听小骨假体

Also Published As

Publication number Publication date
AU7432201A (en) 2002-01-08
GB0015430D0 (en) 2000-08-16

Similar Documents

Publication Publication Date Title
WO2002000275A1 (fr) Materiaux polymeriques biocompatibles
US10660990B2 (en) Article with foamed surface, implant and method of producing the same
US7923486B2 (en) Bio-polymer and scaffold-sheet method for tissue engineering
WO2002000270A1 (fr) Materiaux polymeres biocompatibles
WO2002002158A1 (fr) Materiaux polymeres biocompatibles
CA2730771A1 (fr) Matieres polymeres
US20070036844A1 (en) Porous materials having multi-size geometries
JP2006512171A (ja) 網状エラストマーマトリックス、その製造および埋込み可能な装置での使用
Wang et al. Porous bioactive scaffold of aliphatic polyurethane and hydroxyapatite for tissue regeneration
JP2012505947A (ja) ポリマー材料
US12076463B2 (en) Method of making an osteoconductive polymer article and an osteoconductive polymer article thus made
US8431623B2 (en) Process for forming a porous PVA scaffold using a pore-forming agent
KR100942822B1 (ko) 폴리파라디옥사논-카프로락톤 블록 공중합체를 포함하는 조직 재생용 지지체
WO2003103925A1 (fr) Melanges de polymeres composites a phase cocontinue pour des applications biomedicales in-vivo et in-vitro
TWI241199B (en) Method for manufacturing porous bioresorbable material having interconnected pores
KR100737167B1 (ko) 조직공학용 다공성 뼈-연골 복합 지지체의 제조 방법
WO2002000271A1 (fr) Materiaux polymeres biocompatibles
WO2002049688A1 (fr) Materiaux polymeres biocompatibles
WO2002000762A1 (fr) Materiaux polymeres fonctionnalises
WO2002000763A1 (fr) Materiaux polymeres biocompatibles
TWI445761B (zh) 一種生物可分解吸收複合材料、其製備方法及其應用
EP1559685A2 (fr) Dispositifs changeant de dimensions et de formes par pression osmotique
US20240197958A1 (en) Hybrid, artificial bone tissue implant absorbing mechanical vibrations, whose architectural structure imitates trabecular bone, allowing the saturation of bone marrow, blood, and nutrients, supporting autological regeneration, which can be used with titanium structures
Tanaka 2D and 3D biocompatible polymers for biomedical devices
BR112020006640B1 (pt) Método de fabricação de um artigo de polímero osteocondutor e implante ortopédico

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP